Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Active not recruiting 10Terminated 7Recruiting 7Withdrawn 3Not yet recruiting 3Completed 3Unknown 1Approved for marketing 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Healthy Adults 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumor 1

Interventions

Cyclophosphamide 1495Cisplatin 1431Paclitaxel 1339Radiotherapy 1308Carboplatin 1264Gemcitabine 1225Docetaxel 1134Bevacizumab 1068Fluorouracil 906Doxorubicin 799Dexamethasone 753Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 693Etoposide 674Irinotecan 639Filgrastim 624Nivolumab 585Cytarabine 585Leucovorin 582Vincristine 512Cetuximab 478Prednisone 477Bortezomib 472Trastuzumab 469Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 443Lenalidomide 434

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × adagrasib × Clear all
NCT04330664 2025-04-04

Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

Mirati Therapeutics Inc.

Phase 1 Completed
86 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT05178888 2025-02-11

Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)

Mirati Therapeutics Inc.

Phase 1 Completed
11 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT05924152 2024-03-13

A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib

Mirati Therapeutics Inc.

Phase 1 Completed
16 enrolled

Healthy Adults

Data powered by HemOnc (CC BY 4.0) Colophon âš¡